Jennison Associates
NRIX icon

Jennison Associates’s Nurix Therapeutics NRIX Stock Holding History

Jennison Associates’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-43,181
Closed -$563K – 610
2022
Q3 		$563K Sell
43,181
-553
-1% -$8.75K ﹤0.01% 576
2022
Q2 		$554K Sell
43,734
-21
-0% -$238 ﹤0.01% 592
2022
Q1 		$613K Sell
43,755
-867,249
-95% -$15.4M ﹤0.01% 607
2021
Q4 		$26.4M Sell
911,004
-8,215
-0.9% -$249K 0.02% 317
2021
Q3 		$27.5M Buy
919,219
+182
+0% +$5.62K 0.02% 323
2021
Q2 		$24.4M Sell
919,037
-957
-0.1% -$28.1K 0.02% 345
2021
Q1 		$28.6M Buy
919,994
+721,743
+364% +$27.3M 0.02% 305
2020
Q4 		$6.52M Sell
198,251
-1,909
-1% -$63.3K ﹤0.01% 440
2020
Q3 		$6.99M Buy
+200,160
New +$5.04M 0.01% 410

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates's NRIX Position: Q4 2022 in Review

Jennison Associates sold out of Nurix Therapeutics (NRIX) in Q4 2022, closing a stake of 43,181 shares — an estimated $563K sold.

Jennison Associates first reported a position in NRIX in Q3 2020 and held it in 9 quarters. The position peaked at $28.6M in Q1 2021. 119 funds tracked by Wall St. Rank hold NRIX as of Q4 2022.

  • Jennison Associates reported no remaining Nurix Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Jennison Associates sold 43,181 Nurix Therapeutics shares in Q4 2022, an estimated $563K.
  • Jennison Associates first reported a position in Nurix Therapeutics in Q3 2020 and held it in 9 quarters.
  • Jennison Associates's Nurix Therapeutics position peaked at $28.6M in Q1 2021.
  • 119 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2022.

Based on Jennison Associates's 13F filing for Q4 2022, filed 9 Feb 2023.